Gentofte Hospital
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Gentofte Hospital the cardiology unit is investigating novel approaches to improve outcomes for patients with heart failure with preserved ejection fraction and those living with atrial fibrillation, aiming to assess both efficacy and safety of emerging therapies.
- Evaluating colchicine’s impact on health status in HFpEF
- Comparing asundexian with standard anticoagulant apixaban for stroke prevention
- Assessing bleeding risk and overall benefit‑risk profile of new oral anticoagulants
The program involves 30 investigators and supports six active trials, reflecting the department’s commitment to advancing cardiovascular care in Denmark.
Respiratory Tract Diseases
Research in the respiratory department targets chronic lung conditions such as chronic obstructive pulmonary disease and fibrotic lung disease, focusing on innovative treatments and immune‑based strategies.
- Live‑vaccine induction of trained immunity to lower systemic inflammation in COPD
- Long‑term safety and tolerability of inhaled treprostinil for IPF/PPF patients
- Exploring novel inhaled therapies to improve lung function and quality of life
These studies aim to expand therapeutic options for patients with severe respiratory disorders while ensuring rigorous safety monitoring.
Cell Physiological Phenomena
The site examines fundamental cellular processes that drive disease, including how cells respond to pharmacologic interventions in both cardiac and pulmonary contexts.
- Investigation of cellular pathways underlying trained immunity after vaccination
- Mechanistic studies of colchicine’s effect on cardiomyocyte function
- Cellular response profiling to inhaled treprostinil in fibrotic lung tissue
By linking cellular insights to clinical outcomes, the research supports precision medicine initiatives across multiple therapeutic areas.
Immune System Phenomena
A key focus is the modulation of the immune system, assessing how interventions shape innate and adaptive responses in diseases like COPD and atrial fibrillation.
- Characterization of innate immune changes following live‑vaccine exposure in COPD patients
- Monitoring immune safety signals during anticoagulant therapy with asundexian
- Evaluating systemic inflammation markers as predictors of treatment success
These investigations aim to harness immune mechanisms to improve disease management and reduce adverse events.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 158 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 151 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1Gentofte Hospital9active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Gentofte Hospital20trials
lock +15 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gentofte Hospital
lock Showing 1 of 78 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Shionogi Protease Inhibitor (S-217622) | University Of Minnesota | Phase III | Not Recruiting | Jul 2023 | Oct 2025 |
IMP list
lock Showing 1 of 158 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Colchicine | 5 | Unknown | 2021-08-10 | 2025-12-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.